BBS Faculty Member - Sudha Biddinger

Sudha Biddinger

Department of Pediatrics

Boston Children's Hospital
CLS Building, Room 16027
300 Longwood Ave
Boston, MA 02115
Tel: 617-919-2864
Fax: 617-730-0244
Lab Members: 3 postdoctoral fellows, 1 clinical fellow, 3 graduate students, and 2 technicians
Visit my lab page here.

The metabolic syndrome, which affects almost 33% of adult Americans, is a constellation of symptoms, including hyperglycemia and dyslipidemia, which promote the development of atherosclerosis, fatty liver disease, and gallstones. Insulin resistance was postulated to play a central role in the metabolic syndrome over twenty years ago. Since then, we have accumulated a large body of data showing a correlation between insulin resistance, the metabolic syndrome, and its sequelae. How insulin resistance promotes the development and progression of the metabolic syndrome, though, remains unclear, hampering our ability to treat these disorders.

The overall mission of the Biddinger lab is to identify better treatments for individuals with the metabolic syndrome. The primary goal of our research is to dissect the specific signaling pathways and molecules by which insulin regulates lipid metabolism, and how this becomes dysregulated in the metabolic syndrome. To accomplish this goal, we will integrate biochemical, molecular, cellular, proteomic and mouse genetic approaches with clinical studies in humans.

Last Update: 6/18/2014


For a complete listing of publications click here.



Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB. Hepatic Insulin Signaling Is Required for Obesity-Dependent Expression of SREBP-1c mRNA but Not for Feeding-Dependent Expression. Cell Metab. 2012;15(6):873-84.

Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic
syndrome. Curr Opin Lipidol. 2009;20(3):206-10.

Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7(2):125-34.

Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, Unterman TG, Carey MC, Kahn CR. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14(7):778-82.

© 2016 President and Fellows
of Harvard College